Literature DB >> 20189276

A case series of proton pump inhibitor-induced hypomagnesemia.

Ewout J Hoorn1, Joost van der Hoek, Rob A de Man, Ernst J Kuipers, Clemens Bolwerk, Robert Zietse.   

Abstract

Proton pump inhibitor (PPI)-induced hypomagnesemia has been recognized since 2006. Our aim was to further characterize the clinical consequences and possible mechanisms of this electrolyte disorder using 4 cases. Two men (aged 63 and 81 years) and 2 women (aged 73 and 62 years) had been using a PPI (esomeprazole, pantoprazole, omeprazole, and rabeprazole, 20-40 mg) for 1-13 years. They developed severe hypomagnesemia (magnesium, 0.30 +/- 0.28 mEq/L; reference, 1.40-2.10 mEq/L) with hypocalcemia (calcium, 6.4 +/- 1.8 mg/dL), relative hypoparathyroidism (parathyroid hormone, 43 +/- 6 pg/mL), and extremely low urinary calcium and magnesium excretion. One patient was admitted with postanoxic encephalopathy after a collapse likely caused by arrhythmia. The others had electrocardiogram abnormalities (prolonged QT interval, ST depression, and U waves). Concomitant hypokalemia (potassium, 2.8 +/- 0.1 mEq/L) was considered the trigger for these arrhythmias. Hypomagnesemia-induced kaliuresis (potassium excretion, 65 +/- 24 mEq/L) was identified as the cause of hypokalemia. This series of PPI-induced hypomagnesemia shows that this is a generic effect. It also indicates that hypomagnesemia may occur within 1 year of PPI therapy initiation and can have serious clinical consequences, likely triggered by the associated hypokalemia. A high index of suspicion is required in PPI users for unexplained hypomagnesemia, hypocalcemia, hypokalemia, or associated symptoms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20189276     DOI: 10.1053/j.ajkd.2009.11.019

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  66 in total

1.  Proton pump inhibitor associated hypomagnasaemia - a cause for concern?

Authors:  Joe Begley; Trevor Smith; Kirsty Barnett; Paul Strike; Adnan Azim; Claire Spake; Tristan Richardson
Journal:  Br J Clin Pharmacol       Date:  2016-01-25       Impact factor: 4.335

2.  Acute neurological symptoms secondary to hypomagnesemia induced by proton pump inhibitors: a case series.

Authors:  Luca Pasina; Danilo Zanotta; Silvana Puricelli; Guido Bonoldi
Journal:  Eur J Clin Pharmacol       Date:  2016-02-13       Impact factor: 2.953

3.  Proton pump inhibitor-induced hypomagnesemia: A new challenge.

Authors:  Matilda Florentin; Moses S Elisaf
Journal:  World J Nephrol       Date:  2012-12-06

4.  Proton pump inhibitor-associated hypomagnesaemia and hypocalcaemia.

Authors:  Christopher Morris; Peter Pillans
Journal:  Aust Prescr       Date:  2017-04-03

5.  Seizure and tetany secondary to hypomagnesaemic hypoparathyroidism induced by a proton-pump inhibitor.

Authors:  Luca Pasina; Danilo Zanotta; Silvana Puricelli; Guido Bonoldi
Journal:  Eur J Clin Pharmacol       Date:  2016-11-28       Impact factor: 2.953

6.  Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?

Authors:  Alexander L Fohl; Randolph E Regal
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-06-06

Review 7.  A benefit-risk assessment of the use of proton pump inhibitors in the elderly.

Authors:  Gwen M C Masclee; Miriam C J M Sturkenboom; Ernst J Kuipers
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

8.  Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients.

Authors:  Charlotte Van Ende; Steven Van Laecke; Celine Marechal; Francis Verbeke; Nada Kanaan; Eric Goffin; Raymond Vanholder; Michel Jadoul
Journal:  J Nephrol       Date:  2014-05-10       Impact factor: 3.902

9.  Evaluation of electrolyte repletion in hematopoietic cell transplant patients receiving H-2 receptor antagonists or proton pump inhibitors.

Authors:  K Smith; M L Gatesman; S E Harpe; W Clark
Journal:  Bone Marrow Transplant       Date:  2014-05-12       Impact factor: 5.483

10.  Proton-pump inhibitor use is associated with low serum magnesium concentrations.

Authors:  John Danziger; Jeffrey H William; Daniel J Scott; Joon Lee; Li-wei Lehman; Roger G Mark; Michael D Howell; Leo A Celi; Kenneth J Mukamal
Journal:  Kidney Int       Date:  2013-01-16       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.